HDAC6 Antibody - #AF6485

(5)   (3)  
Product: HDAC6 Antibody
Catalog: AF6485
Description: Rabbit polyclonal antibody to HDAC6
Application: WB IHC IF/ICC
Reactivity: Human, Mouse
Mol.Wt.: 131kDa; 131kD(Calculated).
Uniprot: Q9UBN7
RRID: AB_2835165

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse
Clonality:
Polyclonal
Specificity:
HDAC6 Antibody detects endogenous levels of total HDAC6.
RRID:
AB_2835165
Cite Format: Affinity Biosciences Cat# AF6485, RRID:AB_2835165.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CPBHM; FLJ16239; HD 6; HD6; HDAC 6; HDAC6; HDAC6_HUMAN; Histone deacetylase 6 (HD6); Histone deacetylase 6; JM 21; JM21; KIAA0901; OTTHUMP00000032398; OTTHUMP00000197663; PPP1R90; Protein phosphatase 1 regulatory subunit 90;

Immunogens

Immunogen:
Uniprot:

Q9UBN7(HDAC6_HUMAN) >>Visit HPA database.

Gene(ID):
HDAC6(10013)
Description:
Histones play a critical role in transcriptional regulation, cell cycle progression, and developmental events. Histone acetylation/deacetylation alters chromosome structure and affects transcription factor access to DNA.
Sequence:
MTSTGQDSTTTRQRRSRQNPQSPPQDSSVTSKRNIKKGAVPRSIPNLAEVKKKGKMKKLGQAMEEDLIVGLQGMDLNLEAEALAGTGLVLDEQLNEFHCLWDDSFPEGPERLHAIKEQLIQEGLLDRCVSFQARFAEKEELMLVHSLEYIDLMETTQYMNEGELRVLADTYDSVYLHPNSYSCACLASGSVLRLVDAVLGAEIRNGMAIIRPPGHHAQHSLMDGYCMFNHVAVAARYAQQKHRIRRVLIVDWDVHHGQGTQFTFDQDPSVLYFSIHRYEQGRFWPHLKASNWSTTGFGQGQGYTINVPWNQVGMRDADYIAAFLHVLLPVALEFQPQLVLVAAGFDALQGDPKGEMAATPAGFAQLTHLLMGLAGGKLILSLEGGYNLRALAEGVSASLHTLLGDPCPMLESPGAPCRSAQASVSCALEALEPFWEVLVRSTETVERDNMEEDNVEESEEEGPWEPPVLPILTWPVLQSRTGLVYDQNMMNHCNLWDSHHPEVPQRILRIMCRLEELGLAGRCLTLTPRPATEAELLTCHSAEYVGHLRATEKMKTRELHRESSNFDSIYICPSTFACAQLATGAACRLVEAVLSGEVLNGAAVVRPPGHHAEQDAACGFCFFNSVAVAARHAQTISGHALRILIVDWDVHHGNGTQHMFEDDPSVLYVSLHRYDHGTFFPMGDEGASSQIGRAAGTGFTVNVAWNGPRMGDADYLAAWHRLVLPIAYEFNPELVLVSAGFDAARGDPLGGCQVSPEGYAHLTHLLMGLASGRIILILEGGYNLTSISESMAACTRSLLGDPPPLLTLPRPPLSGALASITETIQVHRRYWRSLRVMKVEDREGPSSSKLVTKKAPQPAKPRLAERMTTREKKVLEAGMGKVTSASFGEESTPGQTNSETAVVALTQDQPSEAATGGATLAQTISEAAIGGAMLGQTTSEEAVGGATPDQTTSEETVGGAILDQTTSEDAVGGATLGQTTSEEAVGGATLAQTTSEAAMEGATLDQTTSEEAPGGTELIQTPLASSTDHQTPPTSPVQGTTPQISPSTLIGSLRTLELGSESQGASESQAPGEENLLGEAAGGQDMADSMLMQGSRGLTDQAIFYAVTPLPWCPHLVAVCPIPAAGLDVTQPCGDCGTIQENWVCLSCYQVYCGRYINGHMLQHHGNSGHPLVLSYIDLSAWCYYCQAYVHHQALLDVKNIAHQNKFGEDMPHPH

PTMs - Q9UBN7 As Substrate

Site PTM Type Enzyme
S16 Phosphorylation
S22 Phosphorylation P49841 (GSK3B)
S28 Phosphorylation
T30 Phosphorylation
K32 Ubiquitination
K36 Acetylation
K37 Acetylation
S43 Phosphorylation
K51 Ubiquitination
K116 Ubiquitination
S412 Phosphorylation
S458 Phosphorylation P68400 (CSNK2A1)
Y570 Phosphorylation P00533 (EGFR)
S846 Phosphorylation
S847 Phosphorylation
K849 Acetylation
K849 Ubiquitination
K853 Acetylation
K854 Acetylation
K854 Ubiquitination
K860 Ubiquitination
T868 Phosphorylation
K873 Acetylation
K881 Acetylation
T923 Phosphorylation
S925 Phosphorylation
T993 Phosphorylation
S995 Phosphorylation
T1003 Phosphorylation
T1016 Phosphorylation
T1021 Phosphorylation
T1027 Phosphorylation
T1031 Phosphorylation P27361 (MAPK3) , P28482 (MAPK1)
T1034 Phosphorylation
S1035 Phosphorylation P27361 (MAPK3)
T1040 Phosphorylation
T1041 Phosphorylation
T1048 Phosphorylation
T1055 Phosphorylation
S1062 Phosphorylation
K1206 Ubiquitination

Research Backgrounds

Function:

Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. In addition to histones, deacetylates other proteins: plays a central role in microtubule-dependent cell motility by mediating deacetylation of tubulin. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. In addition to its protein deacetylase activity, plays a key role in the degradation of misfolded proteins: when misfolded proteins are too abundant to be degraded by the chaperone refolding system and the ubiquitin-proteasome, mediates the transport of misfolded proteins to a cytoplasmic juxtanuclear structure called aggresome. Probably acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.

PTMs:

Phosphorylated by AURKA.

Ubiquitinated. Its polyubiquitination however does not lead to its degradation.

Sumoylated in vitro.

Subcellular Location:

Cytoplasm. Cytoplasm>Cytoskeleton. Nucleus. Perikaryon. Cell projection>Dendrite. Cell projection>Axon.
Note: It is mainly cytoplasmic, where it is associated with microtubules.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Interacts with SIRT2 (via both phosphorylated, unphosphorylated, active or inactive forms); the interaction is necessary for the complex to interact with alpha-tubulin. Under proteasome impairment conditions, interacts with UBD via its histone deacetylase 1 and UBP-type zinc-finger regions. Interacts with BBIP10, CBFA2T3, CYLD, DDIT3/CHOP, ZMYND15, F-actin and HDAC11. Interacts with RIPOR2; this interaction occurs during early myogenic differentiation and prevents HDAC6 to deacetylate tubulin. Interacts with DYSF; this interaction occurs during early myogenic differentiation. Interacts with TPPP; inhibiting the tubulin deacetylase activity of HDAC6. Interacts with DYNLL1.

Family&Domains:

Belongs to the histone deacetylase family. HD type 2 subfamily.

Research Fields

· Human Diseases > Substance dependence > Alcoholism.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

References

1). Enhanced autophagic clearance of amyloid-β via HDAC6-mediated V-ATPase assembly and lysosomal acidification protects against Alzheimer's disease in vitro and in vivo. Neural regeneration research, 2024 (PubMed: 38993141) [IF=5.9]
2). Enhanced autophagic clearance of amyloid-β via histone deacetylase 6-mediated V-ATPase assembly and lysosomal acidification protects against Alzheimer's disease in vitro and in vivo. Neural regeneration research, 2025 (PubMed: 38993141) [IF=5.9]

Application: WB    Species: Human    Sample: SH-SY5Y cells

Figure 1 HDAC6 knockdown enhances lysosomal acidification in SH-SY5Y cells.HDAC6 was knocked down in SH-SY5Y cells through transfection with shHDAC6. (A) Representative immunoblots for HDAC6, Ac-α-tubulin, and α-tubulin. (B, C) Relative protein expression levels based on band intensity (n = 3 independent experiments). (D) Immunofluorescence staining with antibodies against Ac-α-tubulin (green) and α-tubulin (red). Scale bar: 10 μm. (E) Quantitative analysis of relative Ac-α-tubulin expression levels (n = 30 cells in each group). (F) Representative immunoblots for V-ATPase subunits (ATP6V1A, ATP6V1C1, ATP6V0D) and Lamp2 in membrane fractions from cells subjected to HDAC6 knockdown. (G, H) Ratios of ATP6V1A and ATP6V1C1 to ATP6V0D, reflecting V-ATPase V1-V0 assembly (n = 3 independent experiments). (I) Relative ATP6V0D expression, normalized to Lamp2 expression, based on band density (n = 3 independent experiments). (J) Lamp2 immunofluorescence (red). Scale bar: 5 μm. (K, L) Size and number of Lamp2-positive puncta in cells transfected with shHDAC6 or shCTRL (n = 30 cells in each group). (M) LysoSensor yellow/blue DND-160 lysosomal acidification detection. Scale bar: 5 μm. (N) The degree of acidity is presented by the ratio of yellow to blue puncta (n = 30 cells in each group). (O) Calibration curve for lysosomal pH. (P) Lysosomal pH values in shCTRL and shHDAC6 SH-SY5Y cells (n = 5 independent cultures). *P < 0.05, **P < 0.01, ***P < 0.001 (two-tailed Student’s t-test). Ac-α-tubulin: Acetylated-α-tubulin; ex: excitation; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; HDAC6: histone deacetylase 6; ns: not significant; shHDAC6: HDAC6 shRNA.
3). Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. Journal of Applied Toxicology, 2023 (PubMed: 36861143) [IF=2.7]

Application: WB    Species: Human    Sample: Caco-2 cells

FIGURE 6 HDAC6 inhibition restored HTRA1 expression in iAs-exposed Caco-2 cells. (A) RT-qPCR result showed the transcript level of HTRA1 in cells from the Ctrl and iAs groups treated with WT-161 (5 μM); DMSO was used as control. (B) The protein levels of HDAC6 and HTRA1 in response to WT-161 treatment were determined by Western blot analysis. (C) Apoptosis of cells treated with panobinostat (100 nM), WT-161 (5 μM), and mocetinostat (1 μM) for 48 h was examined by cytotoxicity assay. The sensitivity of the treatment of WT-161 (5 μM), 5-FU (6 μM) or the combination of these drugs for 48 h was analyzed by (D) cytotoxicity assay and (E) DNA fragmentation ELISA. Data were representatives of at least three independent experiments, shown as mean ± SD. The Significance threshold for one-way ANOVA:
4). NWD1 influences the extension of neuronal axons by regulating microtubule stability. Biochemical and biophysical research communications, 2024 (PubMed: 39383832) [IF=2.5]
5). Emodin inhibits HDAC6 mediated NLRP3 signaling and relieves chronic inflammatory pain in mice. Experimental and therapeutic medicine, 2024 (PubMed: 38144917) [IF=2.4]

Application: WB    Species: Mouse    Sample:

Effect of emodin treatment on HDAC6 activity. (A) The modeled 3D structure of HDAC6 docked with emodin. (B) An enlarged view of the binding site is displayed in the inset box. (C) The interaction bonds of HDAC6 with emodin. The HDAC6 protein is shown in cyan, emodin is colored green, the interacting residues as red, bonds are shown as yellow dotted lines and bond lengths are depicted as numbers. (D) Representative immunofluorescence staining images and (E) quantitative intensity analysis of HDAC6 of each group. Scale bar, 20 µm. Representative (F) western blots and (G) quantitation of HDAC6 expression levels. Data are presented as the mean ± SD (n=5). *P

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.